Ripretinib - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for ripretinib and what is the scope of freedom to operate?
Ripretinib
is the generic ingredient in one branded drug marketed by Deciphera Pharms and is included in one NDA. There are thirty-five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Ripretinib has eighty-seven patent family members in twenty-three countries.
Summary for ripretinib
International Patents: | 87 |
US Patents: | 35 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 33 |
Clinical Trials: | 12 |
Patent Applications: | 112 |
What excipients (inactive ingredients) are in ripretinib? | ripretinib excipients list |
DailyMed Link: | ripretinib at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ripretinib
Generic Entry Date for ripretinib*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ripretinib
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Pfizer | Phase 1/Phase 2 |
Asan Medical Center | Phase 2 |
Theseus Pharmaceuticals | Phase 1/Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for ripretinib
US Patents and Regulatory Information for ripretinib
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for ripretinib
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Deciphera Pharmaceuticals (Netherlands) B.V. | Qinlock | ripretinib | EMEA/H/C/005614 Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. |
Authorised | no | no | yes | 2021-11-18 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ripretinib
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 101110530 | ⤷ Sign Up | |
Brazil | 112022013169 | COMPOSIÇÕES DE 1-(4-BROMO-5-(1-ETIL-7-(METILAMINO)-2-OXO-1,2-DIIDRO-1,6-NAFTIRIDIN-3-IL)-2-FLUOROFEIL)-3-FENILUREA | ⤷ Sign Up |
Croatia | P20231699 | ⤷ Sign Up | |
European Patent Office | 2063897 | INHIBITEURS DE KINASES UTILES POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES (KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES) | ⤷ Sign Up |
Australia | 2023241368 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea | ⤷ Sign Up |
European Patent Office | 4013335 | SYSTÈME D'ORIENTATION RACHIDIEN (SPINAL ORIENTATION SYSTEM) | ⤷ Sign Up |
Lithuania | 4084778 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |